Clinical Trials Browser

Phase 2 × Carcinoma, Renal Cell × trebananib × Clear all

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase 2 Completed

41 enrolled 13 charts

Carcinoma, Renal Cell

NCT00467025 2016-03-23

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Phase 2 Completed

Carcinoma, Renal Cell